Sol-gel Technologies Ltd. revenue

Sol-gel Technologies Ltd.'s revenue was $19.4m in fiscal 2025, up 68.0% on the year before. Since fiscal 2017 ($174,000) it has grown at a compound 80.2% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sol-gel Technologies Ltd.: revenue history, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	23	9	31	4	2	12	19
Growth on the year before	—	−25.9%	+>999%	−61.7%	+256.5%	−87.6%	−60.0%	+642.5%	+68.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Sol-gel Technologies Ltd.	$19.4m	68.0%	—
Zhengye Biotechnology Holding Ltd	$16.2m	-37.5%	—
Jaguar Health, Inc.	$27.8m	135.5%	76.5%
Verrica Pharmaceuticals Inc.	$30.3m	106.2%	52.2%
Scilex Holding Co	$31.6m	-28.5%	-12.0%
Sunshine Biopharma Inc.	$35.3m	-2.7%	34.5%

Compare with peers

Head to head: SLGL vs ZYBT JAGX vs SLGL SLGL vs VRCA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Sol-gel Technologies Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Sol-gel Technologies Ltd.